The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes

Aug 3, 2024European heart journal. Quality of care & clinical outcomes

Cost-effectiveness of semaglutide for lowering heart disease risk in overweight and obese people with heart disease but no diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

The incremental cost-effectiveness ratios for semaglutide are A$99,853 per year of life saved and A$96,055 per quality-adjusted life year gained.

Semaglutide may reduce cardiovascular outcomes in individuals with cardiovascular disease and obesity.
Modeling over 20 years indicated that semaglutide's annual cost is A$4,175.
The cost-effectiveness analysis suggests that semaglutide is not cost-effective at the current price in Australia.
A price reduction to ≤A$2,000 annually or targeted use in high-risk patients could improve its cost-effectiveness.

AI simplified

BACKGROUND AND AIMS: The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial demonstrated significant reductions in cardiovascular outcomes in people with cardiovascular disease (CVD) and overweight or obesity (but without diabetes). However, the cost of the medication has raised concerns about its financial viability and accessibility within healthcare systems. This study explored whether the use of semaglutide for the secondary prevention of CVD in overweight or obesity is cost-effective from the Australian healthcare perspective.

METHODS AND RESULTS: A Markov model was developed based on the SELECT trial to model the clinical outcomes and costs of a hypothetical population treated with semaglutide vs. placebo, in addition to standard care, and followed up over 20 years. With each annual cycle, subjects were at risk of having non-fatal CVD events or dying. Model inputs were derived from SELECT and published literature. Costs were obtained from Australian sources. All outcomes were discounted by 5% annually. The main outcome of interest was the incremental cost-effectiveness ratio (ICER) in terms of cost per year of life saved (YoLS) and cost per quality-adjusted life year (QALY) gained. With an annual estimated cost of semaglutide of A$4175, the model resulted in ICERs of A$99 853 (US$143 504; £40 873) per YoLS and A$96 055 (US$138 046; £39 318) per QALY gained.

CONCLUSION: Assuming a willingness-to-pay threshold of A$50 000, semaglutide is not considered cost-effective at the current price. A price of ≤A$2000 per year or more targeted use in high-risk patients would be needed for it to be considered cost-effective in the Australian setting.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text ↗

The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief